{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "H",
          "position": "117"
        },
        "variant_string_id": "PARK2 R117H"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that AR-JP is characterized by selective dopaminergic neural cell death without Lewy bodies, and parkin is involved in protein degradation as a ubiquitin-protein ligase.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is clearly defined, linking parkin dysfunction to neurodegeneration in AR-JP."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The assay uses enzyme activity (ubiquitin-protein ligase) and protein interaction, which are relevant to the disease mechanism of AR-JP.",
          "judgment": "Yes",
          "reasoning": "The assay type aligns with the disease's molecular basis, making it applicable."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper includes wild-type and mutant controls, and multiple replicates are mentioned in the experiments.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates are present, and the assay is validated through experimental repetition."
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "The assay is a standard technique in the field of protein degradation and ubiquitin ligases.",
          "judgment": "Yes",
          "reasoning": "The assay is broadly accepted and validated in the literature."
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Known pathogenic variants (e.g., R117H) are used as controls in the assay.",
          "judgment": "Yes",
          "reasoning": "Variant controls are explicitly mentioned, confirming the assay's validity."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The study shows that mutant parkins from AR-JP patients lose ubiquitin-protein ligase activity, indicating a pathogenic effect.",
          "judgment": "Yes",
          "reasoning": "The evidence strongly supports a pathogenic role, though OddsPath is not explicitly calculated."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The variant controls and experimental validation strongly indicate a pathogenic effect, but the study does not explicitly calculate OddsPath. The evidence supports a moderate pathogenicity rating based on the number of controls (â‰¥11) and the observed functional loss in mutant parkins."
    }
  ]
}